JP2009538898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538898A5 JP2009538898A5 JP2009512684A JP2009512684A JP2009538898A5 JP 2009538898 A5 JP2009538898 A5 JP 2009538898A5 JP 2009512684 A JP2009512684 A JP 2009512684A JP 2009512684 A JP2009512684 A JP 2009512684A JP 2009538898 A5 JP2009538898 A5 JP 2009538898A5
- Authority
- JP
- Japan
- Prior art keywords
- progression
- diabetes
- delaying
- type
- gpr119 agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 claims 4
- 229940100607 GPR119 agonist Drugs 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 150000003384 small molecules Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102100033839 Glucose-dependent insulinotropic receptor Human genes 0.000 description 1
- 101000996752 Homo sapiens Glucose-dependent insulinotropic receptor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013293 zucker diabetic fatty rat Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0610746.0A GB0610746D0 (en) | 2006-06-01 | 2006-06-01 | Method of treatment |
| PCT/GB2007/050313 WO2007138362A1 (en) | 2006-06-01 | 2007-06-01 | Use of gpcr agonists to delay progression of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538898A JP2009538898A (ja) | 2009-11-12 |
| JP2009538898A5 true JP2009538898A5 (enExample) | 2012-12-27 |
Family
ID=36694688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512684A Pending JP2009538898A (ja) | 2006-06-01 | 2007-06-01 | 糖尿病の進行を遅らせるためのｇｐｃｒアゴニストの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090258816A1 (enExample) |
| EP (1) | EP2029124A1 (enExample) |
| JP (1) | JP2009538898A (enExample) |
| GB (1) | GB0610746D0 (enExample) |
| WO (1) | WO2007138362A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2499018T3 (es) | 2007-09-20 | 2014-09-26 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de GPR119 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| US20100130476A1 (en) * | 2008-11-12 | 2010-05-27 | The Scripps Research Institute | Compounds that induce pancreatic beta-cell expansion |
| JP5378825B2 (ja) * | 2009-02-17 | 2013-12-25 | 出光興産株式会社 | Ｇｐｒ１１９アゴニスト |
| GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| US8293729B2 (en) * | 2009-06-24 | 2012-10-23 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| US8481731B2 (en) * | 2009-06-24 | 2013-07-09 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical composition and methods relating thereto |
| JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ |
| GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
| EP2999783A2 (en) * | 2013-05-23 | 2016-03-30 | University of Bremen | Novel treatment of metabolic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100042A (en) * | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
| US8207147B2 (en) * | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| US20090325924A1 (en) * | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
-
2006
- 2006-06-01 GB GBGB0610746.0A patent/GB0610746D0/en not_active Ceased
-
2007
- 2007-06-01 US US12/303,028 patent/US20090258816A1/en not_active Abandoned
- 2007-06-01 WO PCT/GB2007/050313 patent/WO2007138362A1/en not_active Ceased
- 2007-06-01 EP EP07733734A patent/EP2029124A1/en not_active Ceased
- 2007-06-01 JP JP2009512684A patent/JP2009538898A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007169302A5 (enExample) | ||
| CL2007003262A1 (es) | Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades. | |
| JP2006517944A5 (enExample) | ||
| CL2007001992A1 (es) | Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege | |
| CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
| IL184126A0 (en) | Solid, orally applicable pharmaceutical administration forms containing rivaroxaban having modified release | |
| CL2006002831A1 (es) | Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides. | |
| CL2007001993A1 (es) | Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat | |
| CL2007003583A1 (es) | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. | |
| JP2007522094A5 (enExample) | ||
| JP2006503588A5 (enExample) | ||
| JP2008302206A5 (enExample) | ||
| JP2013525444A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| CL2007001597A1 (es) | Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes | |
| JP2007504174A5 (enExample) | ||
| JP2009506117A5 (enExample) | ||
| JP2007302683A5 (enExample) | ||
| IL190618A0 (en) | Solid orally administerable pharmaceutical dosage forms with rapid active principle release | |
| CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
| CL2007001724A1 (es) | Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1 | |
| JP2009536652A5 (enExample) | ||
| JP2007536277A5 (enExample) | ||
| JP2007520565A5 (enExample) | ||
| AR062390A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas |